AddedRisk Factors
We use third-party open-source software in connection with the development and deployment of our software applications. From time to time, companies that use third-party open-source software have faced claims challenging the use of such open-source software and their compliance with the terms of the applicable open-
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
All of the components that go into the manufacturing of our products and services are sourced from a limited number of third-party suppliers predominantly in the U.S., China, Italy, Vietnam, and Japan, and, in particular, around half of the cellulose acetate used to produce many of our frames is provided by a single supplier. Our contract manufacturers purchase many of these components on our behalf. For our business to be successful, our suppliers must be willing and able to provide us with inputs in substantial quantities, in compliance with
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
lengthy interruptions to our business. All of the aforementioned risks may be exacerbated if our business continuity and disaster recovery plans prove to be inadequate.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
changes may materially and adversely impact our business, financial condition, results of operations, and cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
•price our products and services so that we are able to attract new customers, and expand our relationships with existing customers;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•successfully compete with other companies that are currently in, or may in the future enter, the industry or the markets in which we compete, and respond to developments from these competitors such as pricing changes and the introduction of new products and services;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•successfully expand in existing geographic markets and enter new geographic markets, including international markets;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•successfully expand and gain market adoption on our market share by offering customers the ability to pay through managed vision care, vision insurance, and other third-party payors;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•successfully develop new offerings, including new offerings with higher margins, and innovate and enhance our existing products and services and their features, including in response to new trends, competitive dynamics, or the needs of customers;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•successfully identify and acquire or invest in businesses, products, or technologies that we believe could complement or expand our business;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•provide customers with a high-quality experience and customer service and support that meets their needs;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•hire, integrate, and retain talented sales, customer experience, product design, and development and other personnel, including vision care professionals;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•effectively manage growth of our business, personnel, and operations, including new retail store openings;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•effectively manage our costs related to our business and operations, including increased costs related to tariffs; and
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Because we have a limited history operating our business at its current scale, it is difficult to evaluate our current business and future prospects, including our ability to plan for and model future growth. Our limited operating experience at this scale, combined with the rapidly evolving nature of the market in which we sell our products and services, substantial uncertainty concerning how these markets may develop, and other economic factors beyond our control, reduces our ability to accurately forecast quarterly or annual revenue. Failure to manage our future growth effectively could have an adverse effect on our business, financial condition, and operating results.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
▪recruit and retain store managers, personnel and qualified vision care professionals (who may be licensed or unlicensed, depending on state regulations) for any new store;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
Moreover, the vertically integrated nature of our business, where we design all of our own glasses in our New York headquarters, contract manufacture all of our glasses frames, fulfill the glasses we sell at our own optical and fulfillment laboratories as well as at third-party contract laboratories, sell our products exclusively through our own retail stores, e-commerce site and mobile application, and service our products, business exposes us to risk and disruption at many points that are critical to successfully operating our business, and may make it more difficult for us to scale our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
There is also no guarantee that our pending trademark applications for any mark will proceed to registration; our Our pending applications may be opposed by a third party parties prior to registration; registration, and even those our registered trademarks that are registered could be challenged by a third party, including by way of revocation or invalidity actions. parties.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any provision in our certificate of incorporation, our bylaws, or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our Class A common stock, and could also affect the price that some investors are willing to pay for our Class A common stock.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the FDA may change its policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay marketing authorization of our products (or modifications to our products), may increase the costs of compliance, or impact otherwise adversely affect our ability to modify any products for which we or our third-party manufacturers have already obtained marketing authorizations on a timely basis. business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In recent years, the U.S. government has implemented tariffs on specified products imported into the United States from China and, as a result, costs with respect to our products subject to these in 2025, the U.S. government announced new or heightened tariffs have increased. on product imports from certain countries, including China, Italy, Vietnam and Japan.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We rely heavily on our information technology systems, as well as those of our third-party vendors, business partners, and service providers, for our business to effectively operate and to safeguard confidential information; any Any significant failure, inadequacy, interruption, or cybersecurity incident could adversely affect our business, financial condition, and operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Despite our precautions, it may be possible for unauthorized third parties to copy our offerings and capabilities and use information that or to register our trademarks or other trademarks similar to our trademarks in jurisdictions before we regard as proprietary do, leading to create offerings that compete with ours. brand confusion or dilution.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, as discussed above, in 2018, we experienced a credential stuffing attack attack, in which malicious third parties used credentials compromised in data breaches suffered by other companies to access accounts on our platform platform, and received notice that OCR the Office for Civil Rights (“OCR”) would be investigating the incident and our compliance with the Privacy, Security, and Breach Notification Rules and requesting certain information related to the incident and our compliance with the Privacy, Security, and Breach Notification Rules.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
As and if To the extent we expand our operations into new geographies, the scale effects of our international business activities, any changes being subject to taxation in the United States or foreign taxation of such activities jurisdictions may increase our worldwide effective tax rate and harm our business, financial condition, and results of operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The As a public company, we are subject to the reporting requirements of these the Exchange Act, the listing standards of the NYSE, and other applicable securities rules and regulations regulations, which have increased and will likely continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems, and resources.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Increases in component costs, shipping costs, long lead times, supply shortages, and supply changes could disrupt Disruptions to our supply chain and factors such as wage rate increases and inflation can have a material adverse effect on our business, financial condition, and operating results.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We continuously evaluate our systems landscape landscape, and we may have to upgrade been undertaking a multi-year process of upgrading our IT systems or implement new technology systems from time to time systems, including our ERP system, in order to support the needs of our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In several many states where we operate, state corporate practice of medicine and optometry laws prohibit a business corporation from practicing medicine or optometry, directly employing physicians or optometrists to provide professional services, or exercising control over treatment decisions by such professionals.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Litigation brought to protect and enforce our intellectual property rights could be costly, time-consuming, and distracting to management, may not be successful, and could result in the impairment or loss of portions of our intellectual property rights.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Any of these events could harm adversely affect our business and cause our results of operations, liquidity, and financial condition to suffer.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In the second quarter of 2025, we announced a partnership with Google to develop AI-enabled glasses intended for all-day wear. We are working closely with Google on the development of AI glasses and intend to launch a series of products over time. As part of this collaboration, Google has committed up to $75 million for our product development and commercialization costs. In addition, Google has committed to investing up to $75 million in Warby Parker, at our option and subject to reaching certain collaboration milestones. During the year ended December 31, 2025, the Company reduced selling, general, and administrative expenses by $3.3 million related to costs which are reimbursable by Google and are thus fully offset within the period.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The nature of our business, which involves the sale of products and services that are a medical necessity for many consumers, provides some insulation from swings in consumer sentiment. However, our performance and growth are still subject to broader macroeconomic factors. During 2025, we experienced pressure from a dynamic trade environment and fluctuating inflationary trends, which impacted both consumer discretionary spending and our internal cost structure. While elevated interest rates and government policy continue to influence consumer confidence, we remain focused on our core value proposition to mitigate these headwinds.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Our 2025 results were affected by cost volatility related to evolving international trade policies and tariffs. We have taken proactive steps to manage these costs, including further diversifying our supplier base outside of China, making strategic price adjustments on select products, and disciplined expense management. The complexity of the global trade landscape makes it difficult to predict the timing and extent of future policy changes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We believe our business model, which emphasizes an outstanding value-driven experience, provides a durable foundation. Our ongoing efforts to expand our supply chain network, both through international frame manufacturing partnerships and our domestic optical laboratories, are a key strategy intended to insulate us from localized disruptions. While we continue to navigate these macroeconomic uncertainties, we remain committed to meeting growing customer demand while maintaining our exceptional quality and customer satisfaction standards.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(4) Represents one-time inventory write-downs primarily related to the decision in the second quarter of 2025 to sunset our Home-Try On program at the end of 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Cost of goods sold includes the costs incurred to acquire materials, assemble, and sell our finished products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
compensation, mostly related to the 2021 Founders Grant. As a percentage of revenue, SG&A decreased by 460 basis points, primarily driven by slower growth in corporate expenses, efficiencies in our customer experience operations, and reduced stock-based compensation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In February 2026, the Company’s Board of Directors authorized a share repurchase program to purchase up to $100.0 million of the Company’s Class A common stock (the “Share Repurchase Program”). Repurchases under the Share Repurchase Program may be made in the open market, in privately negotiated transactions, or otherwise, with the amount and timing of repurchases to be determined at the Company’s discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. The Share Repurchase Program does not have a fixed expiration date, does not obligate the Company to acquire any
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
particular amount of Class A common stock, and may be modified, suspended, or terminated at any time at the discretion of the Company’s Board of Directors.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
The nature of our business, which involves the sale of products and services that are a medical necessity for many consumers, provides some insulation from swings in consumer sentiment and general economic conditions. However, our performance and growth are still impacted by these factors. Elevated inflation and interest rates, tariffs, and other negative economic factors may impact consumer spending habits as well as our cost of attracting and our ability to attract new customers. We believe our business model, focused on providing an exceptional value and experience to our customers, will help mitigate the impact of many of these macroeconomic factors, however, the extent of such mitigation and the impact on future results is uncertain. We also continue to diversify and expand our supply chain network, both internationally with our frame manufacturers and domestically with our wholly owned and partner optical laboratories, which we believe helps to insulate us from supply chain disruption and allowed us to continue to meet growing customer demand over the last several years while maintaining our exceptional quality and customer satisfaction standards.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
As of December 31, 2024, 236 out of our 276 retail stores offered in-person eye exams.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(3) Represents the amortization of costs capitalized in connection with the implementation of cloud-based software.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We recognize compensation expense for stock-based awards based on the grant date fair value, on a straight-line basis over the requisite service period of the awards, which is generally the vesting term of the outstanding stock awards. Compensation expense for performance awards is recognized when it is determined that it is probable that the vesting conditions will be satisfied.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
In June 2021, we granted 4,397,688 PSUs and 1,884,724 RSUs to the Co-CEOs, in the aggregate, under the 2019 Plan (the “Founders Grant”). The PSUs vest upon two performance conditions, (i) a qualified public offering and (ii) the price of our Class A common stock reaches stock price hurdles over a period of ten years, as defined by the terms of the award. The PSUs are subject to the Co-CEOs’ continued employment with the Company through the applicable vesting date.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We used a Monte Carlo simulation to calculate the grant-date fair value of the PSUs of $128.8 million. Since the PSUs contain a performance and market condition, the stock-based compensation expense is recognized when it becomes probable that the performance condition will be met using the accelerated attribution method. Stock-based compensation is recognized over the period of time the market condition for each tranche is expected to be met (i.e., the derived service period). The derived service period over which the expense is expected to be recognized is 3.8 years. The qualified public offering performance condition was satisfied at September 29, 2021 by our direct listing, and we began recording expense at that time.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The Founders Grant RSUs vest in equal monthly installments over a period of five years, subject to the Co-CEOs’ continued employment with the Company through the applicable vesting date and conditioned upon the completion of a qualified public offering. The grant-date fair value of the RSUs is $66.9 million. Since the RSUs contain a performance condition, stock-based compensation expense is recognized using the accelerated attribution method when it becomes probable that the performance condition will be met. The performance condition was satisfied on September 29, 2021 by our direct listing, and we began recording expense at that time.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
The decrease in gross margin was primarily driven by the tariff costs related to glasses, sales growth of contact lenses lenses, which are sold at a lower margin than our other eyewear, increased doctor salaries, headcount as the number of exam stores offering eye exams grew, grew by 21%, and increases in store occupancy increased customer shipping costs as a percent of revenue as we grew our store base from 200 stores as revenue, partially offset by selective price increases in glasses taken in the second quarter and increased penetration of December 31, 2022 to 237 stores as of December 31, 2023. progressives and other lens enhancements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was primarily driven by higher payroll-related costs, primarily payroll related costs from growth in our retail workforce, workforce and investments in marketing, partially offset by a $23.2 million decrease in lower stock-based compensation, mostly related to the Founders Grant (as described in Note 7 to our consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cost of goods sold was primarily driven by increased product and fulfillment costs associated with our sales growth, particularly related to the growth in our contact lens offering, as well as increases in store occupancy, store depreciation, doctor headcount due to new retail stores opened in 2024, offering and optical laboratory costs to support glasses growth. growth, as well as increases in store occupancy costs and doctor headcount due to new retail stores.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Interest and other income, net (8,379) (10,596) (9,232) (1,307) Provision for income taxes 1,402 875 433 497 Depreciation and amortization expense 50,280 45,865 38,554 31,864 Asset impairment charges 557 816 3,230 1,647 Stock-based compensation expense(1) 36,097 48,409 71,065 98,655 Non-cash charitable donations(2) 2,821 2,196 3,191 3,770 Amortization of cloud-based software implementation costs(3) costs 3,405 3,704 2,895 247 ERP System implementation costs(4) costs(3) 1,883 — 4,413 687 Inventory write-downs(4) 2,456 — — Other costs(5) 3,048 2,232 1,000 1,535 Adjusted EBITDA $ 95,211 $ 73,111 $ 52,352 $ 27,202 Adjusted EBITDA Margin 10.9 % 9.5 % 7.8 % 4.5 %
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The changes in operating assets and liabilities were primarily driven by decreased inventory as we more closely manage stock on hand, increased accrued expenses, increases in accounts payable and increased net lease liabilities and a decrease in connection with retail leases entered into in 2024, inventory, partially offset by an increase in prepaid expenses and other current assets.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, net cash provided by used in financing activities was $5.0 $12.0 million, which was primarily related to cash paid for shares withheld for taxes for stock-based compensation, partially offset by proceeds from stock option exercises, shares issued in connection with our Employee Stock Purchase Plan (“ESPP”), and other equity activity. (“ESPP”).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
(5) Represents employee severance Primarily represents restructuring costs incurred in the second quarter of 2025 and related costs for restructuring actions executed in October the fourth quarter of 2024 and August 2022 and charges for certain legal matters outside the ordinary course of business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
(2) Represents charitable expense recorded in connection with the donation of 178,572 shares of Class A common stock in each of May 2025, May 2024, and August 2023 and May 2022 to the Warby Parker Impact Foundation, and 56,938 shares of Class A common stock to charitable donor advised funds in June 2023, and 34,528 shares of Class A common stock to charitable donor advised funds in November 2022. 2023.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
(1) Represents expenses related to the Company’s equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions, as well as the issuance of 48,486 shares of Class A common stock to charitable donor advised funds in February 2024. conditions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Provision for income taxes increased $0.4 $0.5 million, or 102.1%, 60.2%, for the year ended December 31, 2024 2025 compared to the same period in 2023 2024 primarily due to the change in pre-tax loss income (loss) in addition to the tax effects of stock-based compensation expense, expense and depreciation expense, and differences in tax rates in state jurisdictions. expense.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net revenue 100.0% 100.0% 100.0% Cost of goods sold 46.0% 44.7% 45.5% 43.0% Gross profit 54.0% 55.3% 54.5% 57.0% Selling, general, and administrative expenses 54.6% 59.2% 65.3% 75.6% Loss from operations (0.6)% (3.9)% (10.8)% (18.6)% Interest and other income, net 1.0% 1.4% 1.4% 0.2% Loss Income (loss) before income taxes 0.4% (2.5)% (9.4)% (18.4)% Provision for income taxes 0.2% 0.1% —% 0.1% Net loss income (loss) 0.2% (2.6)% (9.4)% (18.5)%
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 ($ in thousands) Net cash provided by operating activities $ 110,785 $ 98,744 $ 60,991 $ 10,370 Net cash used in investing activities (67,048) (66,032) (54,671) (60,181) Net cash (used in) provided by financing activities 4,961 (11,997) 4,959 2,871 3,291 Effect of exchange rates on cash 457 (404) (882) (1,311) Net increase (decrease) in cash and cash equivalents $ 32,197 $ 37,267 $ 8,309 $ (47,831)
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new